Concord Biotech Ltd
Fundamental Score
Concord Biotech Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of CONCORDBIO across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (21.27%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (42.73%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Consistent Growth Track Record (18.56% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (18.55% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (1342.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹428.88 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 46.19x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-33.59%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-20.35%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Earnings Growth (-26.61% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Concord Biotech Ltd
About CONCORDBIO
Business Overview
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Company Details
Key Leadership
Corporate Events
CONCORDBIO Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Concord Biotech Ltd (CONCORDBIO)?
As of 09 Feb 2026, 12:21 pm IST, Concord Biotech Ltd (CONCORDBIO) is currently trading at ₹1272.20. The stock has a market capitalization of ₹14.96K (Cr).
Is CONCORDBIO share price Overvalued or Undervalued?
CONCORDBIO is currently trading at a P/E ratio of 46.19x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Concord Biotech Ltd share price?
Key factors influencing CONCORDBIO's price include its quarterly earnings growth (Sales Growth: -20.35%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Concord Biotech Ltd a good stock for long-term investment?
Concord Biotech Ltd shows a 5-year Profit Growth of 18.55% and an ROE of 21.27%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing.
How does Concord Biotech Ltd compare with its industry peers?
Concord Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare CONCORDBIO's P/E of 46.19x and ROE of 21.27% against the industry averages to determine its competitive standing.
What is the P/E ratio of CONCORDBIO and what does it mean?
CONCORDBIO has a P/E ratio of 46.19x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹46 for every ₹1 of annual earnings.
How is CONCORDBIO performing according to Bull Run's analysis?
CONCORDBIO has a Bull Run fundamental score of 56.3/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does CONCORDBIO belong to?
CONCORDBIO operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Concord Biotech Ltd.
What is Return on Equity (ROE) and why is it important for CONCORDBIO?
CONCORDBIO has an ROE of 21.27%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Concord Biotech Ltd generates profits from shareholders' equity.
How is CONCORDBIO's debt-to-equity ratio and what does it indicate?
CONCORDBIO has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is CONCORDBIO's dividend yield and is it a good dividend stock?
CONCORDBIO offers a dividend yield of 0.75%, which means you receive ₹0.75 annual dividend for every ₹100 invested.
How has CONCORDBIO grown over the past 5 years?
CONCORDBIO has achieved 5-year growth rates of: Sales Growth 18.56%, Profit Growth 18.55%, and EPS Growth -26.61%.
What is the promoter holding in CONCORDBIO and why does it matter?
Promoters hold 44.08% of CONCORDBIO shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is CONCORDBIO's market capitalization category?
CONCORDBIO has a market capitalization of ₹14962 crores, placing it in the Mid-cap category.
How volatile is CONCORDBIO stock?
CONCORDBIO has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for CONCORDBIO?
CONCORDBIO has a 52-week high of ₹N/A and low of ₹N/A.
What is CONCORDBIO's operating profit margin trend?
CONCORDBIO has a 5-year average Operating Profit Margin (OPM) of 42.73%, indicating the company's operational efficiency.
How is CONCORDBIO's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -20.35% and YoY Profit Growth of -33.59%.
What is the institutional holding pattern in CONCORDBIO?
CONCORDBIO has FII holding of 8.03% and DII holding of 9.55%. Significant institutional holding often suggests professional confidence in the stock.